



**HAL**  
open science

## **Haloperidol regulates the state of phosphorylation of ribosomal protein S6 via activation of PKA and phosphorylation of DARPP-32**

Gilberto Fisone, Emmanuel Valjent, Jesus Bertran-Gonzalez, Heather Bowling, Sébastien Lopez, Emanuela Santini, Miriam Matamales, Alessandra Bonito-Oliva, Denis Hervé, Charles Hoeffler, et al.

► **To cite this version:**

Gilberto Fisone, Emmanuel Valjent, Jesus Bertran-Gonzalez, Heather Bowling, Sébastien Lopez, et al.. Haloperidol regulates the state of phosphorylation of ribosomal protein S6 via activation of PKA and phosphorylation of DARPP-32. *Neuropsychopharmacology*, 2011, 10.1038/npp.2011.144 . hal-00665873

**HAL Id: hal-00665873**

**<https://hal.science/hal-00665873>**

Submitted on 3 Feb 2012

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**Haloperidol regulates the state of phosphorylation of ribosomal protein S6 via activation of PKA and phosphorylation of DARPP-32**

Emmanuel Valjent,<sup>1#</sup> Jesus Bertran-Gonzalez,<sup>2,3,4</sup> Heather Bowling,<sup>5</sup> Sébastien Lopez,<sup>1</sup> Emanuela Santini,<sup>1</sup> Miriam Matamales,<sup>2,3,4</sup> Alessandra Bonito-Oliva,<sup>1</sup> Denis Hervé,<sup>2,3,4</sup> Charles Hoeffler,<sup>5</sup> Eric Klann,<sup>5</sup> Jean-Antoine Girault,<sup>2,3,4</sup> Gilberto Fisone<sup>1</sup>

<sup>1</sup>Department of Neuroscience, Karolinska Institutet, 17177 Stockholm, Sweden;

<sup>2</sup>INSERM, UMR-S839, 75005 Paris, France; <sup>3</sup>Université Pierre et Marie Curie, 75005

Paris, France; <sup>4</sup>Institut du Fer à Moulin, 75005 Paris, France; <sup>5</sup>Center for Neural

Science, New York University, New York, 10003 New York, USA.

<sup>#</sup>Current address: Institut de Génomique Fonctionnelle, INSERM U661, CNRS UMR

5203, University Montpellier I and II, 141, rue de la Cardonille, 34094 Montpellier

Cedex 05

*Running title:* Haloperidol regulation of ribosomal protein rpS6

Corresponding author:  
Gilberto Fisone  
Department of Neuroscience  
Karolinska Institutet  
Retzius väg 8  
17177 Stockholm, Sweden  
Phone: +46-8-52487375  
Fax: +46-8-320988  
gilberto.fisone@ki.se

## **Abstract**

Administration of typical antipsychotic drugs, such as haloperidol, promotes cAMP-dependent signaling in the medium spiny neurons (MSNs) of the striatum. In this study, we have examined the effect of haloperidol on the state of phosphorylation of the ribosomal protein S6 (rpS6), a component of the small 40S ribosomal subunit. We found that haloperidol increases the phosphorylation of rpS6 at the dual site Ser235/236, which is involved in the regulation of mRNA translation. This effect was exerted in the MSNs of the indirect pathway, which express specifically dopamine D2 receptors (D2Rs) and adenosine A2 receptors (A2ARs). The effect of haloperidol was decreased by blockade of A2ARs or by genetic attenuation of the  $G\alpha_{olf}$  protein, which couples A2ARs to activation of adenylyl cyclase. Moreover, stimulation of cAMP-dependent protein kinase (PKA) increased Ser235/236 phosphorylation in cultured striatal neurons. The ability of haloperidol to promote rpS6 phosphorylation was abolished in knock in mice deficient for PKA activation of the protein phosphatase-1 inhibitor, dopamine and cAMP-regulated phosphoprotein of 32 kDa. In contrast, pharmacological or genetic inactivation of p70 rpS6 kinase 1, or extracellular signal-regulated kinases did not affect haloperidol-induced rpS6 phosphorylation. These results identify PKA as a major rpS6 kinase in neuronal cells and suggest that regulation of protein synthesis through rpS6 may be a potential target of antipsychotic drugs.

*Key words:* antipsychotics; adenosine A2A receptor; dopamine D2 receptor; medium spiny neurons; protein phosphatase-1; striatum.

## **Introduction**

The ability to antagonize neurotransmission at dopamine D2 receptors (D2Rs) is generally regarded as an important feature of drugs used in the treatment of schizophrenia and other psychotic disorders (Creese *et al*, 1976). However, blockade of D2Rs leads to the development of irreversible side-effects, including tardive dyskinesia and parkinsonism, which seriously hamper the use of effective medications. These motor disorders have been proposed to depend on the ability of antipsychotic drugs to affect neurotransmission in the dorsal striatum, a major component of the basal ganglia (Robertson and Fibiger, 1992; Wan *et al*, 1995). In this region, D2Rs are selectively expressed by a large group of GABAergic medium spiny neurons (MSNs), which project to the external segment of the globus pallidus (Gerfen, 1992). Acting through a polysynaptic circuit, these cells modulate the activity of thalamo-cortical neurons involved in the control of motor function (Albin *et al*, 1989; Gerfen, 1992). For these reasons, striatopallidal MSNs are thought to play a critical role in the motor side effects associated to the use of antipsychotic drugs.

One of the primary actions exerted in the brain by conventional antipsychotics, such as haloperidol, is to promote cAMP-dependent signaling, which is normally inhibited by D2Rs through activation of Gi/o proteins (Stoof and Kebabian, 1981). In striatopallidal MSNs, haloperidol-induced activation of cAMP-dependent protein kinase (PKA) and of the protein phosphatase-1 (PP-1) inhibitor, dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32), has been proposed to affect gene transcription by acting on nuclear targets, including the cAMP response element-binding protein and histone H3 (Bertran-Gonzalez *et al*, 2009; Konradi and Heckers, 1995; Li *et al*, 2004; Pozzi *et al*, 2003). Much less is known about the ability

of antipsychotic drugs and of the PKA/DARPP-32 cascade to affect signaling cascades involved in translational control.

The ribosomal protein S6 (rpS6) is a component of the small 40S ribosomal subunit implicated in mRNA decoding (Ruvinsky and Meyuhas, 2006). rpS6 is phosphorylated at multiple sites, comprised between Ser235 and Ser247, by the p70 rpS6 kinase (S6K) 1 (Bandi *et al*, 1993; Krieg *et al*, 1988), which is a major downstream effector of the mammalian target of rapamycin complex 1 (mTORC1) (Costa-Mattioli *et al*, 2009). Phosphorylation of rpS6 at the dual site Ser235/236 occurs also independently of mTORC1, via the p90 rpS6 kinases (RSK), which are activated by the extracellular signal-regulated kinases (ERK) (Roux *et al*, 2007; Sturgill *et al*, 1988). Recent studies performed in pancreatic  $\beta$ -cells identified PKA as an additional rpS6 kinase, specifically involved in the phosphorylation of Ser235/236 (Moore *et al*, 2009).

S6K-dependent phosphorylation of rpS6 plays an important role in the control of cell size (Pende *et al*, 2004; Ruvinsky *et al*, 2005) and protein synthesis-dependent plasticity, such as long-term potentiation (Antion *et al*, 2008). In addition, phosphorylation at Ser235/236 has been proposed to promote protein synthesis by facilitating rpS6 recruitment to the 5' cap complex, during the formation of the pre-initiation translation complex (Roux *et al*, 2007). In this study, we examined the ability of haloperidol to regulate rpS6 phosphorylation in the MSNs of the dorsal striatum. We show that haloperidol increases the phosphorylation of rpS6 at Ser235/236, and that this effect is independent of ERK and mTORC1-mediated activation of S6K1, but requires intact PKA/DARPP-32 signaling.

## Materials and Methods

### *Animals*

Male C57BL/6J mice (25-30 g) were purchased from Taconic (Tornbjerg, Denmark). Bacterial artificial chromosomes transgenic mice expressing EGFP under the control of the promoter for the D2R (*Drd2*-EGFP) or the dopamine D1 receptor (D1R; *Drd1a*-EGFP) were generated by the GENSAT (Gene Expression Nervous System Atlas) program at the Rockefeller University (Gong *et al*, 2003) and were crossed on a C57BL/6 background for at least 3 generations. Knock-in mice expressing a mutated form of DARPP-32, in which Thr34 is replaced by Ala (DARPP-32 T34A mutant mice), and *Gnal*<sup>+/-</sup> ( $G\alpha_{olf}$ ) heterozygous mice were generated as described in previous studies (Belluscio *et al*, 1998; Svenningsson *et al*, 2003) and were backcrossed for at least 10 generations on a C57BL/6 background. S6K1 knockout mice were generated via direct gene replacement with a neomycin cassette (previously described in (Shima *et al*, 1998) and were then outcrossed as described in (Antion *et al*, 2008). Animals were maintained in a 12-h light-dark cycle, in stable conditions of temperature (22°C), with food and water *ad libitum*. All experiments were carried out in accordance with the guidelines of the Swedish Animal Welfare Agency, the French Agriculture and Forestry Ministry (decree 87849, license A75-05-22), or the guidelines of the New York University Institutional Animal Care and Use Committee.

### *Drugs*

Haloperidol (0.5 mg/kg, Sigma-Aldrich, Sweden) was dissolved in saline containing 0.05% (vol/vol) acetic acid and the pH was adjusted to 6.0 with 1 M NaOH.

Clozapine (5 mg/kg, Sigma-Aldrich, France) was dissolved in 0.9% NaCl. KW6002 (3 mg/kg) and SL327 (50 mg/kg), gifts from Dr. Edilio Borroni (Hoffmann-La Roche, Basel, Switzerland), were suspended by sonication in a solution of 5% (vol/vol) Tween 80 in saline and administered 5 and 30 min before haloperidol, respectively. Rapamycin (LC Laboratories, Woburn, MA, USA) (5 mg/kg) was dissolved in a solution of 5% dimethylsulfoxide (DMSO), 15% PEG-400 and 5% Tween-20, and was administered (once per day) in a volume of 5 ml/kg body weight, starting 3 days prior to administration of haloperidol. All drugs were injected intraperitoneally (i.p.). Mice were habituated to handling and saline injection for three consecutive days before the experiment. For the chronic experiment, mice were injected once daily with vehicle or haloperidol (0.5 mg/kg) for a period of 15 days and perfused 15 min after a challenge injection with vehicle or haloperidol.

#### *Primary culture of striatal neurons*

Striata were dissected from embryos (E14) of OF1 mice (Charles River Laboratories France) and mechanically dissociated. Striatal cells were suspended in Neurobasal medium (Invitrogen) supplemented with B27 (Invitrogen), 0.5 mM L-glutamine, 100 units/mL penicillin, and 100 µg/mL streptomycin and then plated onto 35 cm culture dishes coated with poly-L-lysine, at 37°C in 5% CO<sub>2</sub>. Every 3–4 days, half of the medium was removed and replaced with fresh medium. After 16 days of culture, neurons were treated with drugs and incubations were stopped by replacing the medium with 0.2 mL of boiling SDS (1%, w/v). Protein concentration was determined by the BCA (bicinchoninic acid) assay kit (Pierce). Samples containing 30 µg of protein were analyzed by electrophoresis on 12% polyacrylamide gels and were subjected to separation and western blotting as described below for brain samples.

### *Immunofluorescence*

Mice were rapidly anaesthetized with pentobarbital (500 mg/kg, i.p., Sanofi-Aventis, France) and transcardially perfused with 4% (weight/vol) paraformaldehyde in 0.1 M sodium phosphate buffer (pH 7.5) (Valjent *et al*, 2000). Brains were post-fixed overnight in the same solution and stored at 4°C. Thirty µm-thick sections were cut with a vibratome (Leica, France) and stored at -20°C in a solution containing 30% (vol/vol) ethylene glycol, 30% (vol/vol) glycerol and 0.1 M sodium phosphate buffer, until they were processed for immunofluorescence. Brain regions corresponding to the dorsal striatum were identified using a mouse brain atlas (Franklin and Paxinos, 1997) and sections at 1.10 mm from bregma were taken. Free-floating sections were rinsed in Tris-buffered saline (TBS; 0.25 M Tris and 0.5 M NaCl, pH 7.5), incubated for 5 min in TBS containing 3% H<sub>2</sub>O<sub>2</sub> and 10% methanol (vol/vol), and then rinsed three times for 10 min each in TBS. After 20 min incubation in 0.2% Triton X-100 in TBS, sections were rinsed three times in TBS again. Finally, rpS6 phosphorylation was analyzed by incubating sections overnight with rabbit polyclonal antibodies against phospho-Ser235/236-rpS6 (1:500, Cell Signalling Technology, Beverly, MA). NaF (0.1 mM) was included in all buffers and incubation solutions. In some experiments, the expression of Gα<sub>oIF</sub> protein in wild type and *Gnal* +/- mice was assessed using rabbit polyclonal antibodies (1:500) (Herve *et al*, 2001). Sections were then rinsed three times for 10 min in TBS and incubated for 45 minutes with goat Cy3-coupled (1:400, Jackson Laboratory, Bar Harbor, ME) secondary antibody. Sections were rinsed for 10 min twice in TBS and twice in TB (0.25 M Tris) before mounting in Vectashield (Vector Laboratories, Burlingame, CA) or 1,4-diazabicyclo-[2.2.2]-octane (DABCO, Sigma-Aldrich Sweden AB, Stockholm). Single- and double-labeled images from each region of interest were obtained bilaterally using



sequential laser scanning confocal microscopy (Leica SP2 and Zeiss LSM510). Neuronal quantification was performed in 375 x 375  $\mu\text{m}$  images by counting Cy3-immunofluorescent nuclei (for phospho-Ser235/236-rpS6 immunolabeling). Cell counts were done by an observer unaware of the treatment received by the mice. A home-written program based on Metamorph software (Molecular Devices, Sunnyvale, CA) was used to compute all parameters.

### *Western blotting*

Mice were killed by decapitation, their heads were cooled in liquid nitrogen for 6 seconds and the brains were removed. The striata were dissected out on an ice-cold surface, sonicated in 750  $\mu\text{l}$  of 1% SDS and boiled for 10 min. Aliquots (5  $\mu\text{l}$ ) of the homogenate were used for protein determination using a BCA (bicinchoninic acid) assay kit (Pierce Europe, Oud Beijerland, the Netherlands). Equal amounts of protein (30  $\mu\text{g}$ ) for each sample were loaded onto 10% polyacrylamide gels. Proteins were separated by sodium dodecylsulfate-polyacrylamide gel electrophoresis and transferred overnight to PVDF membranes (Amersham Pharmacia Biotech, Uppsala, Sweden) (Towbin *et al*, 1979). The membranes were immunoblotted using antibodies against phospho-Ser235/236-rpS6, phospho-Thr389-S6K, phospho-Thr202/Tyr204-ERK1/2 (Cell Signaling Technology, Beverly, MA, USA) and phospho-Thr34-DARPP-32 (Snyder *et al*, 1992). Antibodies against rpS6, S6K (Cell Signaling Technology, Beverly, MA, USA) and DARPP-32 (Hemmings and Greengard, 1986) that are not phosphorylation state specific were used to estimate the total amount of proteins. Detection was based on fluorescent secondary antibody binding and quantified using a Li-Cor Odyssey infrared fluorescent detection system (Li-Cor, Lincoln, NE) or with enhanced chemiluminescence reagent (GE Healthcare). The

levels of each phosphoprotein were normalized for the amount of the corresponding total protein detected in the sample.

#### *Statistical Analysis*

Data were analyzed using one- or two-way ANOVA, and *post hoc* comparisons between groups were made using Bonferroni, or Newman-Keuls *post hoc* multiple comparison tests and T-tests with equal variances for groups of 2, when relevant.

## Results

### **Haloperidol increases rpS6 phosphorylation selectively in D2R-expressing neurons**

Systemic administration of haloperidol at the dose of 0.5 mg/kg, which has been previously shown to promote the phosphorylation of several proteins including PKA substrates (Bertran-Gonzalez *et al*, 2009; Håkansson *et al*, 2006), produced a two-fold increase in the levels of phospho-Ser235/236-rpS6, as determined by western blotting analysis of striatal tissue (Fig. 1A). This effect peaked at 15 min post-injection and declined by 60 min (Fig. 1A). Immunofluorescence analysis revealed a strong increase in the number of phospho-Ser235/236 rpS6-positive neurons in the dorsal striatum following haloperidol administration (Fig. 1B).

In the dorsal striatum, D2Rs are selectively expressed by striatopallidal MSNs, whereas dopamine D1 receptors (D1Rs) are present in the other large group of projection neurons, which form the striatonigral pathway (Gerfen, 1992). To examine the effects of haloperidol on rpS6 phosphorylation in these two neuronal populations, we used transgenic mice expressing EGFP under the control of the promoter for the D2R or D1R (*Drd2*-EGFP and *Drd1a*-EGFP mice) (Gong *et al*, 2003; Valjent *et al*, 2009). We found that the increase in rpS6 phosphorylation induced by haloperidol (0.5 mg/kg) occurred specifically in D2R containing neurons (Fig. 1C and D).

Overall, these results are in line with the ability of this antipsychotic to act specifically at dopamine D2-type receptors and, therefore, to affect preferentially striatopallidal MSNs (Bateup *et al*, 2008; Bertran-Gonzalez *et al*, 2008; Bertran-Gonzalez *et al*, 2009). Interestingly, when administered chronically (one injection per day during two weeks) haloperidol lost the ability to increase rpS6 phosphorylation

(Fig. 1E and F). Therefore, rpS6 phosphorylation is induced selectively in striatopallidal MSNs in response to acute blockade of D2-like receptor, but this effect appears to subside when the duration of treatment is extended.

We also examined the effect on rpS6 phosphorylation of clozapine, an atypical antipsychotic with low affinity for D2Rs. Clozapine (5 mg/kg) increased rpS6 phosphorylation at Ser235/236, selectively in D2R-expressing MSNs (Figure S1). However, this effect was much lower and less sustained than that produced by haloperidol (cf. Fig. 1C and D).

### **Haloperidol-induced phosphorylation at Ser235/236 does not require mTORC1 and S6K1 and is independent of ERK**

S6Ks are primarily involved in the regulation of rpS6 (Bandi *et al*, 1993; Krieg *et al*, 1988; Pende *et al*, 2004; Ruvinsky *et al*, 2005). Therefore, we examined their involvement in haloperidol-induced phosphorylation at Ser235/236. Administration of the mTORC1 inhibitor, rapamycin, prevented phosphorylation of S6K at Thr389 (Fig. 2C), but did not affect phosphorylation of rpS6 at Ser235/236 (Fig. 2A and B). The effect of haloperidol was also tested in mice deficient for S6K1 (Pende *et al*, 2000) (Fig. 2E). In line with the results obtained with rapamycin, we found that, in these animals, the ability of haloperidol to increase rpS6 phosphorylation at Ser235/236 was preserved (Fig. 2D).

Other protein kinases that phosphorylate rpS6 on Ser235/236 are the p90 ribosomal S6 kinases (RSK), which are activated by ERK (Roux *et al*, 2007). The ERK/RSK cascade accounts for the remaining phosphorylation of rpS6 on Ser235/236 observed in S6K1/S6K2 double knock out mice (Pende *et al*, 2004). We therefore examined the involvement of this pathway in rpS6 phosphorylation. We

found that blockade of ERK (Fig. 3C), achieved using SL327 [an inhibitor of the mitogen-activated protein kinase/ERK kinase (MEK)], did not affect the increase in rpS6 phosphorylation produced by haloperidol (Fig. 3A and B).

### **Haloperidol-induced phosphorylation of rpS6 depends on adenosine A2A receptor-mediated activation of $G\alpha_{olf}$**

The data presented above indicate that, in striatal neurons, the two major pathways known to control rpS6 phosphorylation at Ser235/236 are not involved in its regulation in response to haloperidol. Therefore, we examined the possible role of the cAMP-dependent cascade. In addition to D2Rs, striatopallidal MSNs express high levels of the A2A receptor subtype (A2AR) for adenosine. A2ARs are coupled to a  $G\alpha_{olf}$  protein, which increases cAMP synthesis via activation of adenylyl cyclase (Corvol *et al*, 2001; Kull *et al*, 2000). The ability of D2R antagonists to promote cAMP signaling has been previously shown to depend in large part on intact A2AR-mediated transmission (Bertran-Gonzalez *et al*, 2009; Borgkvist and Fisone, 2007; Håkansson *et al*, 2006; Svenningsson *et al*, 2000). Therefore we examined the effect produced by the selective A2AR antagonist, KW6002, on haloperidol-induced rpS6 phosphorylation. We found that blockade of A2ARs with 3 mg/kg of KW6002 reduced the effect of haloperidol on phosphoSer235/236-rpS6 (Fig. 4A and B).

A similar decrease in haloperidol-induced rpS6 phosphorylation was observed in *Gnal*<sup>+/-</sup> mice carrying a heterozygous mutation of the gene encoding for  $G\alpha_{olf}$ , which reduces the levels of this protein in the striatum (Corvol *et al*, 2007) (Fig. 5). This observation was particularly interesting, since in these mice the levels of  $G\alpha_{olf}$  are decreased by approximately 50% (cf. Fig. 5A), which results in a large reduction of cAMP signaling (Corvol *et al*, 2007). Taken together, these results indicate that

haloperidol increases rpS6 phosphorylation by removing the inhibitory tone normally exerted by D2Rs on A2AR-mediated cAMP production.

We used striatal neurons in culture to further explore whether activation of A2ARs could regulate rpS6 phosphorylation on Ser235/236 through cAMP signaling. Application of the A2AR agonist CPCA (200  $\mu$ M) induced the phosphorylation of rpS6 on Ser235/236 in striatal neurons (Fig. 6A). This effect was mediated by PKA, since it was abolished in the presence of the PKA inhibitor H-89 (50  $\mu$ M) (Fig. 6A). Moreover, Sp-5,6-DCI-cBIMPS (10  $\mu$ M), a cAMP analog and PKA activator, induced a marked increase in rpS6 phosphorylation on Ser235/236 (Fig. 6B). Thus, our results *in vivo* and *in vitro* provide converging evidence that the effect of haloperidol on rpS6 Ser235/236 phosphorylation is mediated by activation of the cAMP pathway.

### **Haloperidol-induced phosphorylation of rpS6 depends on PKA-mediated activation of DARPP-32**

In the striatum, a large part of the effects produced by activation of cAMP signaling depends on DARPP-32 (Nairn *et al*, 2004). PKA-mediated phosphorylation at Thr34 converts DARPP-32 into an inhibitor of PP-1, thereby suppressing the dephosphorylation of numerous effector targets acting downstream of the cAMP/PKA cascade (Greengard, 2001). Haloperidol is known to increase DARPP-32 phosphorylation at Thr34 *in vivo* (Pozzi *et al*, 2003). Western blot analysis revealed a significant increase in the levels of phospho-Thr34-DARPP-32, determined in our experimental conditions 15 and 60 min after administration of haloperidol (Fig. 7A). In order to assess the involvement of DARPP-32 in the haloperidol-mediated phosphorylation of rpS6, we used DARPP-32 T34A mutant mice, in which replacement of Thr34 by Ala prevents PKA-mediated phosphorylation (Fig. 7B). We

found that, in these mice, haloperidol did not produce any change in the state of phosphorylation of rpS6 (Fig. 7C and D). These data point to the PKA/DARPP-32 signaling pathway as a major modulator of rpS6 in striatal neurons and indicate that phosphorylation at Ser235/236 is under the control of PP-1.

## Discussion

This study demonstrates that administration of the antipsychotic drug and D2R antagonist, haloperidol, promotes phosphorylation of rpS6 at Ser235/236, specifically at the level of the MSNs of the indirect, striatopallidal pathway. They also show that this effect is exerted by promoting A2AR-mediated activation of the cAMP/DARPP-32 signaling cascade and that it does not involve activation of S6K, or ERK/RSK.

In striatopallidal neurons, blockade of D2Rs increases the state of phosphorylation of several substrates of PKA (Bertran-Gonzalez *et al*, 2008; Bertran-Gonzalez *et al*, 2009; Håkansson *et al*, 2006; Li *et al*, 2004; Pozzi *et al*, 2003). This effect has been attributed to the removal of the inhibitory tone exerted by D2Rs on adenylyl cyclase, which leads to the accumulation of cAMP and activation of PKA. The ability of D2R antagonists, including haloperidol, to promote cAMP/PKA signaling depends on A2ARs (Bertran-Gonzalez *et al*, 2009; Borgkvist *et al*, 2007; Håkansson *et al*, 2006; Svenningsson *et al*, 2000), which maintain basal adenylyl cyclase activity via activation of  $G\alpha_{olf}$  (Corvol *et al*, 2001). The present results, showing that blockade of A2ARs or reduction of the levels of  $G\alpha_{olf}$  prevent the haloperidol-induced increase in Ser235/236, indicate the importance of PKA in this phenomenon. This idea is further supported by the observation that, in cultured striatal neurons, A2AR-mediated increase in Ser235/236 phosphorylation is blocked by PKA inhibition and is mimicked by PKA activation. These observations are in line with the recent identification of PKA as a third *in vivo* rpS6 kinase in pancreatic  $\beta$ -cells (Moore *et al*, 2009).

The ability of the cAMP/PKA signaling pathway to regulate the activity of downstream target proteins depends on concomitant phosphorylation of DARPP-32 at



Thr34, which suppresses protein dephosphorylation via inhibition of PP-1 (Greengard, 2001). Thus, mutation of DARPP-32 at the PKA phosphorylation site, Thr34, prevents the ability of haloperidol and other D2R antagonists to increase the state of phosphorylation of the GluR1 subunit of glutamate AMPA receptors and of histone H3 (Bertran-Gonzalez *et al*, 2009; Håkansson *et al*, 2006). The present data indicate that a similar mechanism is involved in the regulation of rpS6 phosphorylation exerted by haloperidol at Ser235/236. Thus, the effect of haloperidol depends not only on increased PKA-catalyzed phosphorylation, but also on decreased dephosphorylation exerted by phospho-Thr34-DARPP-32, via inhibition of PP-1. In support of this type of regulation, it has been previously proposed that PP-1 acts as an S6 phosphatase (Belandia *et al*, 1994).

The effect of haloperidol on rpS6 phosphorylation at Ser235/236 is exerted independently of S6K. Thus, administration of rapamycin, which suppresses S6K activity, or deletion of S6K1, does not prevent the ability of the D2R antagonist to promote rpS6 phosphorylation.

It has been shown that the ERK/RSK signaling pathway regulates rpS6 phosphorylation via activation of mTORC1 and S6K (Ma *et al*, 2005; Roux *et al*, 2004). Moreover, ERK has been proposed to regulate rpS6 phosphorylation independently of mTORC1, via RSK-catalyzed phosphorylation at Ser235/236 (Roux *et al*, 2007). Our data show that blockade of ERK, achieved with the MEK inhibitor SL327, does not modify the ability of haloperidol to increase rpS6 phosphorylation. This shows that the modest increase of ERK phosphorylation produced by haloperidol in striatopallidal MSNs (Bertran-Gonzalez *et al*, 2008; Bertran-Gonzalez *et al*, 2009) is not involved in the regulation of rpS6.

Work performed in a mouse model of Parkinson's disease, shows that activation of D1Rs increases the phosphorylation of rpS6 at Ser235/236. This effect, which is exerted selectively in the MSNs of the direct pathway, depends on concomitant activation of ERK (Santini *et al*, 2009). Therefore, it appears that, in the striatum, the state of phosphorylation of rpS6 at the level of the two major neuronal populations (i.e. the MSNs of the direct and indirect pathway) is controlled by distinct signaling mechanisms.

The ability of haloperidol to increase the state of phosphorylation of rpS6 in the dorsal striatum represents a novel mechanism potentially implicated in the action of typical antipsychotic drugs. In particular, the present results suggest that the motor side-effects produced by these substances may be linked to changes in the efficiency of mRNA translation occurring in striatopallidal MSNs. In this regard, it is interesting to note that clozapine, an atypical antipsychotic with low liability for motor complications, produces a much more modest effect on rpS6 phosphorylation in comparison to haloperidol. In line with this observation, it has been shown that haloperidol, but not clozapine, increases the expression of *c-fos* in the dorsal striatum (Robertson *et al*, 1992; Wan *et al*, 1995). It is therefore possible that the emergence of tardive dyskinesia and parkinsonism in response to administration of typical antipsychotic drugs is related to modifications in the activity of striatal MSNs produced through a coordinated action on transcriptional and translational processes.

In conclusion, this study shows that the typical antipsychotic, haloperidol, increases the state of phosphorylation of rpS6 in striatopallidal MSNs independently of mTORC1/S6K and ERK/RSK signaling, through activation of cAMP signaling. The data presented support a model in which blockade of D2Rs promotes PKA-catalyzed phosphorylation of Ser235/236 and suppresses PP-1-mediated

dephosphorylation via DARPP-32. They also raise the possibility that antipsychotic drugs and D2R antagonists affect striatal transmission not only through control of transcriptional process but also via changes in translational efficiency.

**Conflict of interest**

The authors declare no conflict of interest.

**Acknowledgments**

This work was supported by Swedish Research Council grants 20715 and 13482, the Wenner-Gren Foundations and the Agence Nationale de la Recherche (ANR) in the frame of Era-Net NEURON (project ANR-08-NEUR-006-01) (to G.F.), the Fondation pour la Recherche Médicale (FRM) and grant ANR-08-BLAN-0287 (to J.A.G.) the National Institutes of Health grants NS034007 and NS047384 (to E.K.). S.L. was a recipient of a postdoctoral fellowship from the FEBS. A.B.O. was supported by the foundation Blanceflor Boncompagni-Ludovisi, née Bildt. The authors thank Dr. Paul Greengard for providing the T34A DARPP-32 mutant mice.

## References

- Albin RL, Young AB, Penney JB (1989). The functional anatomy of basal ganglia disorders. *Trends Neurosci* **12**(10): 366-375.
- Antion MD, Merhav M, Hoeffler CA, Reis G, Kozma SC, Thomas G, *et al* (2008). Removal of S6K1 and S6K2 leads to divergent alterations in learning, memory, and synaptic plasticity. *Learn Mem* **15**(1): 29-38.
- Bandi HR, Ferrari S, Krieg J, Meyer HE, Thomas G (1993). Identification of 40 S ribosomal protein S6 phosphorylation sites in Swiss mouse 3T3 fibroblasts stimulated with serum. *J Biol Chem* **268**(6): 4530-4533.
- Bateup HS, Svenningsson P, Kuroiwa M, Gong S, Nishi A, Heintz N, *et al* (2008). Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. *Nat Neurosci* **11**(8): 932-939.
- Belandia B, Brautigan D, Martin-Perez J (1994). Attenuation of ribosomal protein S6 phosphatase activity in chicken embryo fibroblasts transformed by Rous sarcoma virus. *Mol Cell Biol* **14**(1): 200-206.
- Belluscio L, Gold GH, Nemes A, Axel R (1998). Mice deficient in G(olf) are anosmic. *Neuron* **20**(1): 69-81.
- Bertran-Gonzalez J, Bosch C, Maroteaux M, Matamales M, Herve D, Valjent E, *et al* (2008). Opposing patterns of signaling activation in dopamine D1 and D2 receptor-

expressing striatal neurons in response to cocaine and haloperidol. *J Neurosci* **28**(22): 5671-5685.

Bertran-Gonzalez J, Hakansson K, Borgkvist A, Irinopoulou T, Brami-Cherrier K, Uziel A, *et al* (2009). Histone H3 phosphorylation is under the opposite tonic control of dopamine D2 and adenosine A2A receptors in striatopallidal neurons. *Neuropsychopharmacology* **34**(7): 1710-1720.

Borgkvist A, Fisone G (2007). Psychoactive drugs and regulation of the cAMP/PKA/DARPP-32 cascade in striatal medium spiny neurons. *Neurosci Biobehav Rev* **31**(1): 79-88.

Corvol JC, Studler JM, Schonn JS, Girault JA, Herve D (2001). G $\alpha$ (olf) is necessary for coupling D1 and A2a receptors to adenylyl cyclase in the striatum. *J Neurochem* **76**(5): 1585-1588.

Corvol JC, Valjent E, Pascoli V, Robin A, Stipanovich A, Luedtke RR, *et al* (2007). Quantitative changes in G $\alpha$ olf protein levels, but not D1 receptor, alter specifically acute responses to psychostimulants. *Neuropsychopharmacology* **32**(5): 1109-1121.

Costa-Mattioli M, Sossin WS, Klann E, Sonenberg N (2009). Translational control of long-lasting synaptic plasticity and memory. *Neuron* **61**(1): 10-26.

Creese I, Burt DR, Snyder SH (1976). Dopamine receptor binding predicts clinical and pharmacological potencies of anti-schizophrenic drugs. *Science* **192**: 481-483.

Franklin KBJ, Paxinos G (1997). *The Mouse Brain in Stereotaxic Coordinates*  
Academic Press: San Diego.

Gerfen CR (1992). The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. *Ann Rev Neurosci* **15**: 285-320.

Gong S, Zheng C, Doughty ML, Losos K, Didkovsky N, Schambra UB, *et al* (2003). A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. *Nature* **425**(6961): 917-925.

Greengard P (2001). The neurobiology of slow synaptic transmission. *Science* **294**(5544): 1024-1030.

Håkansson K, Galdi S, Hendrick J, Snyder G, Greengard P, Fisone G (2006). Regulation of phosphorylation of the GluR1 AMPA receptor by dopamine D2 receptors. *J Neurochem* **96**(2): 482-488.

Hemmings HCJ, Greengard P (1986). DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated phosphoprotein: regional, tissue, and phylogenetic distribution. *J Neurosci* **6**: 1469-1481.

Herve D, Le Moine C, Corvol JC, Belluscio L, Ledent C, Fienberg AA, *et al* (2001). Galpha(olf) levels are regulated by receptor usage and control dopamine and adenosine action in the striatum. *J Neurosci* **21**(12): 4390-4399.

Konradi C, Heckers S (1995). Haloperidol-induced Fos expression in striatum is dependent upon transcription factor cyclic AMP response element binding protein.

*Neuroscience* **65**(4): 1051-1061.

Krieg J, Hofsteenge J, Thomas G (1988). Identification of the 40 S ribosomal protein

S6 phosphorylation sites induced by cycloheximide. *J Biol Chem* **263**(23): 11473-11477.

Kull B, Svenningsson P, Fredholm BB (2000). Adenosine A(2A) receptors are

colocalized with and activate g(olf) in rat striatum. *Mol Pharmacol* **58**(4): 771-777.

Li J, Guo Y, Schroeder FA, Youngs RM, Schmidt TW, Ferris C, *et al* (2004).

Dopamine D2-like antagonists induce chromatin remodeling in striatal neurons through cyclic AMP-protein kinase A and NMDA receptor signaling. *J Neurochem* **90**(5): 1117-1131.

Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP (2005).

Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. *Cell* **121**(2): 179-193.

Moore CE, Xie J, Gomez E, Herbert TP (2009). Identification of cAMP-dependent

kinase as a third in vivo ribosomal protein S6 kinase in pancreatic beta-cells. *J Mol Biol* **389**(3): 480-494.



Nairn AC, Svenningsson P, Nishi A, Fisone G, Girault JA, Greengard P (2004). The role of DARPP-32 in the actions of drugs of abuse. *Neuropharmacology* **47**: 14-23.

Pende M, Kozma SC, Jaquet M, Oorschot V, Burcelin R, Le Marchand-Brustel Y, *et al* (2000). Hypoinsulinaemia, glucose intolerance and diminished beta-cell size in S6K1-deficient mice. *Nature* **408**(6815): 994-997.

Pende M, Um SH, Mieulet V, Sticker M, Goss VL, Mestan J, *et al* (2004). S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. *Mol Cell Biol* **24**(8): 3112-3124.

Pozzi L, Hakansson K, Usiello A, Borgkvist A, Lindskog M, Greengard P, *et al* (2003). Opposite regulation by typical and atypical anti-psychotics of ERK1/2, CREB and Elk-1 phosphorylation in mouse dorsal striatum. *J Neurochem* **86**(2): 451-459.

Robertson GS, Fibiger HC (1992). Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. *Neuroscience* **46**(2): 315-328.

Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J (2004). Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. *Proc Natl Acad Sci U S A* **101**(37): 13489-13494.

Roux PP, Shahbazian D, Vu H, Holz MK, Cohen MS, Taunton J, *et al* (2007). RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. *J Biol Chem* **282**(19): 14056-14064.

Ruvinsky I, Meyuhas O (2006). Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. *Trends Biochem Sci* **31**(6): 342-348.

Ruvinsky I, Sharon N, Lerer T, Cohen H, Stolovich-Rain M, Nir T, *et al* (2005). Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. *Genes Dev* **19**(18): 2199-2211.

Santini E, Heiman M, Greengard P, Valjent E, Fisone G (2009). Inhibition of mTOR signaling in Parkinson's disease prevents L-DOPA-induced dyskinesia. *Sci Signal* **2**(80): ra36.

Shima H, Pende M, Chen Y, Fumagalli S, Thomas G, Kozma SC (1998). Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. *EMBO J* **17**(22): 6649-6659.

Snyder GL, Girault JA, Chen JY, Czernik AJ, Keibarian JW, Nathanson JA, *et al* (1992). Phosphorylation of DARPP-32 and protein phosphatase inhibitor-1 in rat choroid plexus: regulation by factors other than dopamine. *J Neurosci* **12**(8): 3071-3083.

Stoof JC, Keibarian JW (1981). Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. *Nature* **294**: 366-368.

Sturgill TW, Ray LB, Erikson E, Maller JL (1988). Insulin-stimulated MAP-2 kinase phosphorylates and activates ribosomal protein S6 kinase II. *Nature* **334**(6184): 715-718.

Svenningsson P, Lindskog M, Ledent C, Parmentier M, Greengard P, Fredholm BB, *et al* (2000). Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptors. *Proc Natl Acad Sci U S A* **97**(4): 1856-1860.

Svenningsson P, Tzavara ET, Carruthers R, Rachleff I, Wattler S, Nehls M, *et al* (2003). Diverse psychotomimetics act through a common signaling pathway. *Science* **302**(5649): 1412-1415.

Towbin H, Staehelin T, Gordon J (1979). Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. *Proc Natl Acad Sci USA* **76**: 4350-4354.

Valjent E, Bertran-Gonzalez J, Herve D, Fisone G, Girault JA (2009). Looking BAC at striatal signaling: cell-specific analysis in new transgenic mice. *Trends Neurosci* **32**(10): 538-547.

Valjent E, Corvol JC, Pages C, Besson MJ, Maldonado R, Caboche J (2000). Involvement of the extracellular signal-regulated kinase cascade for cocaine-rewarding properties. *J Neurosci* **20**(23): 8701-8709.

Wan W, Ennulat DJ, Cohen BM (1995). Acute administration of typical and atypical antipsychotic drugs induces distinctive patterns of Fos expression in the rat forebrain. *Brain Res* **688**(1-2): 95-104.

## Legends to figures

**Figure 1. Effect of haloperidol on rpS6 phosphorylation in striatal MSNs.** (A) Western blot analysis of phospho-Ser235/236-rpS6 (P-235/236-rpS6) in the striata of mice treated with vehicle (Veh) or haloperidol (Hal; 0.5 mg/kg) and killed after 15 or 60 min. Right panels show representative autoradiograms obtained using antibodies against P-235/236-rpS6 (upper) and total rpS6 (lower). Left panel is a summary of data represented as means  $\pm$  SEM (n = 5-7; \*  $p < 0.05$  vs. Veh). (B) Confocal sections of dorsal striata, showing immunofluorescence for P-Ser235/236-rpS6 in mice treated with Veh or Hal and perfused 15 or 60 min later. Scale bar: 40  $\mu$ m. (C-D) Mice expressing EGFP in striatopallidal (*Drd2*-EGFP) or striatonigral (*Drd1a*-EGFP) MSNs were treated with Veh or Hal (0.5 mg/kg) and perfused 15, or 60 min later. (C) Quantification of P-235/236-rpS6 immunoreactive neurons among EGFP-positive (D2-positive) or EGFP-negative (D2-negative) neurons in the dorsal striata of Veh or Hal treated *Drd2*-EGFP mice (\*\* $p < 0.001$  vs. respective Veh). (D) Confocal sections of the dorsal striata of mice treated with Veh or Hal and perfused 15 min later, showing immunofluorescence for P-235/236-rpS6 in combination with EGFP fluorescence. Scale bar: 30  $\mu$ m. (E-F) Mice expressing EGFP in striatopallidal (*Drd2*-EGFP) MSNs were repeatedly treated with Veh or Hal (0.5 mg/kg, one daily injection during 2 weeks) and perfused 15 min after a challenge injection of Veh or Hal. (E) Quantification of P-235/236-rpS6 immunoreactive neurons among EGFP-positive (D2-positive) or EGFP-negative (D2-negative) neurons in the dorsal striata of *Drd2*-EGFP mice treated chronically (15 days) with Veh or Hal and challenged with Veh or Hal (\*\*  $p < 0.001$  vs. Veh; °°  $p < 0.01$  vs. Hal). (F) Confocal sections of the dorsal

striatum, showing immunofluorescence for P-235/236-rpS6 in combination with EGFP fluorescence. Scale bar: 30  $\mu$ m.

**Figure 2. Blockade of mTORC1/S6K signaling does not affect haloperidol-induced phosphorylation of rpS6.** Wildtype mice were treated with vehicle (Veh), haloperidol (Hal; 0.5 mg/kg), or Hal plus rapamycin (5 mg/kg; administered once per day in a volume of 5 ml/kg body weight, starting 3 days prior to administration of Hal) and perfused after 15 or 60 min. (A) Phospho-Ser235/236-rpS6 (P-235/236-rpS6) immunoreactivity in single confocal sections of the dorsal striata of mice treated with vehicle (Veh-Veh), haloperidol (Veh-Hal), or haloperidol plus rapamycin (Rapamycin-Hal) and perfused 15 min later. Scale bar: 30  $\mu$ m. (B) Quantification of P-235/236-rpS6 immunoreactive neurons in the dorsal striata of mice treated with Veh-Veh, Veh-Hal, or Rapamycin-Hal (\*\*  $p < 0.001$  vs. Veh-Veh). (C) Wildtype mice were treated with Veh, Hal (0.5 mg/kg), or Hal plus rapamycin (5 mg/kg; see above) and were killed after 15 min. Representative autoradiogram showing the reduction of phospho-Thr389-S6K immunoreactivity in the striatum of a mouse treated with rapamycin. (D) Wildtype or S6K1 KO mice were treated with vehicle or haloperidol (0.5 mg/kg) and killed 15 min later. Striatal levels of P-235/236-rpS6 were determined by Western blotting. Top panels show representative autoradiograms obtained using antibodies against P-235/236-rpS6 (upper) and total rpS6 (lower). Bottom panel is a summary of data represented as means  $\pm$  SEM (n = 5; \*  $p < 0.05$  vs. respective Veh). (E) Representative autoradiogram showing absence of S6K-immunoreactivity in the striatum of a S6K1 KO mice compared to a wildtype mouse.

**Figure 3. Effect of MEK inhibition on haloperidol-induced phosphorylation of rpS6.** Mice were treated with vehicle (Veh), haloperidol (Hal; 0.5 mg/kg), or Hal plus SL327 (50 mg/kg; administered 45 min prior to administration of Hal) and perfused 15 min later. (A) Phospho-Ser235/236-rpS6 (P-235/236-rpS6) immunoreactivity in single confocal sections of the dorsal striata of mice treated with Hal or Hal plus SL327. Scale bar: 30  $\mu$ m. (B) Quantification of P-235/236-rpS6 immunoreactive neurons in the dorsal striata of mice treated with Veh, Hal, or Hal plus SL327. (\*\*  $p < 0.01$  vs. Veh). (C) Mice were treated with Veh, Hal (0.5 mg/kg), or Hal plus SL327 (50 mg/kg; see above) and killed after 15 min. Representative autoradiogram showing the reduction of phospho-P-ERK immunoreactivity in the striatum of a mouse treated with the MEK inhibitor.

**Figure 4. Effect of KW6002 on haloperidol-induced phosphorylation of rpS6.** Mice were treated with vehicle (Veh), haloperidol (Hal), or Hal plus KW6002 (3 mg/kg; administered 5 min prior to administration of Hal) and perfused 15 or 60 min later. (A) Phospho-Ser235/236-rpS6 (P-235/236-rpS6) immunoreactivity in single confocal sections of the dorsal striatum from mice treated with Hal or Hal plus KW6002. Scale bar: 30  $\mu$ m. (B) Quantification of P-235/236-rpS6 immunoreactive neurons in single confocal sections of the dorsal striata of mice treated with Veh, Hal, or Hal plus KW6002 (\*\*  $p < 0.01$  vs. Veh,  $^{\circ\circ} p < 0.01$  vs. Hal)

**Figure 5.  $G\alpha_{olf}$ -mediated signaling is required for haloperidol-induced rpS6 phosphorylation.** Wildtype ( $Gnal^{+/+}$ ) and  $Gnal^{+/-}$  mice were treated with haloperidol (0.5 mg/kg) and perfused 15 and 60 min later. (A)  $G\alpha_{olf}$  immunoreactivity in single confocal sections of the dorsal striatum from a wild type (WT) or a  $Gnal$

heterozygous ( $Gnal^{+/-}$ ) mouse. Note the decrease in  $G\alpha_{olf}$  immunoreactivity in the striatum of the  $Gnal^{+/-}$  mouse. Scale bar: 50  $\mu$ m. (B) Phospho-Ser235/236-rpS6 (P-235/236-rpS6) immunoreactivity in single confocal sections of the dorsal striatum of  $Gnal^{+/+}$  or  $Gnal^{+/-}$  mice. Scale bar: 30  $\mu$ m. (C) Quantification of P-235/236-rpS6 immunoreactive neurons in the striata of  $Gnal^{+/+}$  and  $Gnal^{+/-}$  mice 15 and 60 min after administration of vehicle (Veh) or haloperidol (Hal) (\*\*  $p < 0.01$  vs. Veh,  $^{\circ}p < 0.01$  vs.  $Gnal^{+/+}$ )

**Figure 6. Effect of PKA signaling on rpS6 phosphorylation.** Western blot analysis of phospho-Ser235/236-rpS6 in striatal neurons in culture. Top panels shows representative autoradiograms. Bottom panels are a summary of data represented as means  $\pm$  SEM (n = 4). (A) Striatal neurons were treated for 15 min with vehicle (Veh), the A2AR agonist 5'-(N-cyclopropyl)carboxamidoadenosine (CPCA, 10  $\mu$ M) or CPCA plus the PKA inhibitor H-89 dihydrochloride hydrate (50  $\mu$ M, added 15 min before CPCA). (B) Striatal neurons were treated for 15 min with Veh or the cAMP analog Sp-5,6-DCI-cBIMPS (cBIMPS, 200  $\mu$ M). (\*\*  $p < 0.01$  vs. Veh,  $^{\circ}p < 0.01$  vs. CPCA).







**Figure 7. Mutation of Thr34 to Ala in DARPP-32 prevents haloperidol-induced histone H3 phosphorylation.** Wildtype and T34A mutant mice were treated with vehicle (Veh) or haloperidol (Hal; 0.5 mg/kg) and perfused 15 and 60 min later. (A) Western blot analysis of phospho-Thr34-DARPP-32 (P-DARPP-32) in the striata of wildtype mice treated with haloperidol (0.5 mg/kg) and killed after 15 or 60 min. Top panels shows representative autoradiograms obtained using antibodies against P-DARPP-32 (upper) and total DARPP-32 (lower). Bottom panel is a summary of data








represented as means  $\pm$  SEM (n = 5-7), (\*  $p < 0.05$  vs. vehicle). (B) Representative autoradiogram confirming the absence of phospho-Thr34-DARPP-32 immunoreactivity in the striata of mice treated with Veh or Hal. (C-D) Wildtype or T34A DARPP-32 mutant mice were treated with Veh or Hal and perfused 15 min or 60 min later. (C) Phospho-Ser235/236-rpS6 (P-235/236-rpS6) immunoreactivity in single confocal sections of the dorsal striata of wildtype or T34A mutant mice. Scale bar: 30  $\mu$ m. (D) Quantification of P-235/236-rpS6 immunoreactive neurons in the dorsal striatum, 15 min or 60 min after administration of Veh or Hal to wildtype or T34A DARPP-32 mutant mice (T34A) (\*\*  $p < 0.01$  vs. Veh,  $^{\circ\circ} p < 0.01$  vs. wildtype).

**Suppl. Figure 1. Effect of clozapine on rpS6 phosphorylation in striatal MSNs.**

Mice were treated with vehicle (Veh) or clozapine (Cpz; 5 mg/kg) and killed after 15 or 60 min. (A) Phospho-Ser235/236-rpS6 (P-235/236-rpS6) immunoreactivity in single confocal sections of the dorsal striata of *Drd2*-EGFP mice treated with Veh or Cpz and perfused 15 min later. Scale bar: 30  $\mu$ m. (B) Quantification of P-235/236-rpS6 immunoreactive neurons among EGFP-positive (D2-positive) or EGFP-negative (D2-negative) neurons in the dorsal striata of *Drd2*-EGFP mice treated with Veh or Cpz and perfused 15 or 60 min later (\*\*  $p < 0.001$  vs. Veh).







**A**


Veh-Hal

SL327-Hal

P-235/236-rpS6

**B**

P-235/236-rpS6 positive neurons

**C**